<table border="1" id="t1232036449" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1:  Clinically Significant Drug Interactions with DILAUDID</caption>
<colgroup>
<col width="23*"></col>
<col width="76*"></col>
</colgroup>
<tbody>
<tr>
<td colspan="2">
<content stylecode="bold">Benzodiazepines and other Central Nervous System
(CNS) Depressants</content>
</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>Due to additive pharmacologic effect, the concomitant use of benzodiazepines
or other CNS depressants, including alcohol, can increase the risk
of hypotension, respiratory depression, profound sedation, coma, and
death.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td>Reserve concomitant prescribing of these drugs for use in patients
for whom alternative treatment options are inadequate. Limit dosages
and durations to the minimum required. Follow patients closely for
signs of respiratory depression and sedation <content stylecode="italics">[see Warnings
and Precautions (<linkhtml href="#Section_5.5">5.5</linkhtml>)]</content>.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers,
muscle relaxants, general anesthetics, antipsychotics, other opioids,
alcohol.</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">Serotonergic Drugs</content>
</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>The concomitant use of opioids with other drugs that affect the
serotonergic neurotransmitter system has resulted in serotonin syndrome</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td>If concomitant use is warranted, carefully observe the patient,
particularly during treatment initiation and dose adjustment.  Discontinue
DILAUDID Oral Solution or DILAUDID Tablets if serotonin syndrome is
suspected.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td>Selective serotonin reuptake inhibitors (SSRIs), serotonin and
norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants
(TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the
serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol),
monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric
disorders and also others, such as linezolid and intravenous methylene
blue).</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>MAOI interactions with opioids may manifest as serotonin syndrome
or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see
Warnings and Precautions (<linkhtml href="#Section_5.3">5.3</linkhtml>)].</content>
<br/>If urgent use of an opioid is necessary, use test doses
and frequent titration of small doses to treat pain while closely
monitoring blood pressure and signs and symptoms of CNS and respiratory
depression.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td>The use of DILAUDID Oral Solution or DILAUDID Tablets is not recommended
for patients taking MAOIs or within 14 days of stopping such treatment.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td>phenelzine, tranylcypromine, linezolid</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist
Opioid Analgesics</content>
</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>May reduce the analgesic effect of DILAUDID Oral Solution or DILAUDID
Tablets and/or precipitate withdrawal symptoms.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td>Avoid concomitant use.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td>butorphanol, nalbuphine, pentazocine, buprenorphine,</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>Hydromorphone may enhance the neuromuscular blocking action of
skeletal muscle relaxants and produce an increased degree of respiratory
depression.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td>Monitor patients for signs of respiratory depression that may
be greater than otherwise expected and decrease the dosage of DILAUDID
Oral Solution or DILAUDID Tablets and/or the muscle relaxant as necessary.</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>Opioids can reduce the efficacy of diuretics by inducing the release
of antidiuretic hormone.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td>Monitor patients for signs of diminished diuresis and/or effects
on blood pressure and increase the dosage of the diuretic as needed.</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">Anticholinergic Drugs</content>
</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>The concomitant use of anticholinergic drugs may increase risk
of urinary retention and/or severe constipation, which may lead to
paralytic ileus.</td>
</tr>
<tr>
<td align="right" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td>Monitor patients for signs of urinary retention or reduced gastric
motility when DILAUDID Oral Solution or DILAUDID Tablets is used concomitantly
with anticholinergic drugs.</td>
</tr>
</tbody>
</table>